IP Library › Granted Patent US 9,574,211
Granted Patent B2
US 9,574,211 · App. 14/711,078 · Granted Feb 21, 2017

Methods and compositions for prevention or treatment of a disease

Inventors: Philip D. Gregory (Richmond, CA); Michael C. Holmes (Richmond, CA)
Assignee: Sangamo BioSciences, Inc.
C12N15/90A61K39/00C07K14/00C12N9/22C07K2319/50C07K2319/71C07K2319/81
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,574,211
App. No.
14/711,078
Granted
Feb 21, 2017
Kind
B2
Abstract

Methods and compositions for treatment of a genetic disease are provided.

Claims (13)

1. A fusion molecule comprising (i) an engineered nuclease that binds to a target site within SEQ NOs:3, 4, 5 or 6 of an endogenous gene that produces a microRNA (miRNA), and (ii) a cleavage domain.

2. A polynucleotide encoding one or more fusion molecules of claim 1 .

3. An isolated cell comprising one or more fusion molecules according to claim 1 .

4. The cell of claim 3 , wherein the cell is a stem cell.

5. The cell of claim 3 , wherein the stem cell is selected from the group consisting of an embryonic stem cell (ESC), an induced pluripotent stem cell (iPSC), a hepatic stem cell and a liver stem cell.

6. The fusion molecule of claim 1 , wherein the engineered nuclease is a zinc finger nuclease.

7. The zinc finger nuclease of claim 6 wherein the endogenous gene is MiR-34 and the zinc finger protein comprises 5 zinc, finger domains, each domain comprising a recognition helix region, wherein the zinc finger protein comprises the recognition helix regions as shown in a single row of Table III.

8. A kit comprising a fusion molecule according to claim 1 .

9. A kit comprising a polynucleotide according to claim 2 .

10. A method of cleaving an endogenous gene that produces an miRNA in a cell, the method comprising:

introducing, into the cell, one or more expression vectors comprising at least one polynucleotide according to claim 2 , under conditions such that the one or more fusion molecules are expressed and the miRNA-producing gene is cleaved.

11. The method of claim 10 , wherein the polynucleotide comprises an AAV vector.

12. The method of claim 10 , wherein the polynucleotide is an mRNA.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 18, 2015
From: GREGORY, PHILIP D.; HOLMES, MICHAEL C.
To: SANGAMO BIOSCIENCES, INC.
Reel/Frame 035660/0493 →
Continuity (2)
Provisional Application 61992676 · May 13, 2014
Related Publication 20150329875A1 · Nov 19, 2015